Physician profile
Robert M Romanoff
NPI 1760456099
$8,325.34
in general payments reported to CMS, 2019-2025
55 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $848 · 2021: $1,052 · 2022: $1,439 · 2023: $1,952 · 2024: $1,597 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,375 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,374.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,004.48 | 2019-2024 | Lokelma, Farxiga, Airsupra |
| Novo Nordisk INC | $782.02 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $701.36 | 2019-2025 | Ubrelvy, Synthroid, Linzess |
| Lilly USA, LLC | $548.94 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Supernus Pharmaceuticals, INC. | $500.00 | 2024 | Qelbree, Xyosted, Tlando |
| Intuity Medical INC | $499.43 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Lundbeck LLC | $468.99 | 2022-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $397.68 | 2022-2024 | Quviviq |
| Amgen INC. | $333.78 | 2019-2023 | Prolia, Evenity |
| Mannkind Corporation | $228.91 | 2019-2024 | Afrezza |
| Sanofi-Aventis U.S. LLC | $222.81 | 2022-2024 | |
| Glaxosmithkline, LLC. | $167.46 | 2019-2023 | Boostrix, Shingrix |
| Gilead Sciences, INC. | $151.56 | 2019-2023 | |
| Abbott Laboratories | $144.05 | 2019-2024 | Freestyle Libre 3 |
| Cequr Corporation | $141.22 | 2022-2025 | Cequr Simplicity |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Romanoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.